Identification of adipose tissue‐derived exosomal microRNA as a novel causal biomarker for cognitive impairment in type 2 diabetes mellitus: Triangulating evidence from Mendelian randomization and multicentre population studies

Aims To explore serum exosomal microRNAs (miRNAs) as risk biomarkers for early detection of cognitive impairment in type 2 diabetes mellitus (T2DM) patients. Materials and Methods This study included two phases: a discovery phase and a validation phase. To detect adipose tissue exosomal biomarkers f...

Full description

Saved in:
Bibliographic Details
Published inDiabetes, obesity & metabolism Vol. 27; no. 3; pp. 1265 - 1275
Main Authors Yang, Sijue, Yuan, Yue, Zhang, Bing, Wu, Tianyu, Yu, Congcong, Li, Fangyi, Zhu, Wenhui, Zhai, Beibei, Zhang, Wen, Wang, Jin, Zhang, Zhou, Bi, Yan
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.03.2025
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN1462-8902
1463-1326
1463-1326
DOI10.1111/dom.16121

Cover

Loading…
More Information
Summary:Aims To explore serum exosomal microRNAs (miRNAs) as risk biomarkers for early detection of cognitive impairment in type 2 diabetes mellitus (T2DM) patients. Materials and Methods This study included two phases: a discovery phase and a validation phase. To detect adipose tissue exosomal biomarkers for T2DM patients, small RNA sequencing was conducted on a discovery population consisting of six T2DM patients and five subjects with normal glucose tolerance. To identify miRNAs with causal effects on cognitive impairment, Mendelian randomization (MR) analysis using publicly available genome wide association studies (GWAS) datasets was performed. Relationships between serum exosomal miRNAs and cognitive impairment were evaluated in a training population of 207 T2DM patients, and further validated in an external population of 101 T2DM patients from multiple centres. Results In the discovery phase, 13 exosomal miRNAs were significantly upregulated in adipose tissue of T2DM patients. MR analyses identified that increased miR‐125a‐5p was causally associated with increased Alzheimer's disease (AD) risk (OR = 1.231, 95% CI 1.062–1.426). In the validation phase, higher serum exosomal miR‐125a‐5p levels were related to increased amnestic mild cognitive impairment (aMCI) risk (OR = 1.066, 95% CI 1.030–1.103) and reduced left hippocampal body volume (r = −0.189, p < 0.05), achieving an area under the curve (AUC) of 0.728 for identifying aMCI in T2DM patients. External validation confirmed a diagnostic AUC of 0.738. Conclusions Serum exosomal miR‐125a‐5p derived from adipose tissue can serve as a causal biomarker for cognitive impairment in T2DM patients.
Bibliography:Sijue Yang, Yue Yuan and Bing Zhang contributed equally to this work.
Prior Presentation: This study has been accepted as an oral abstract presentation (#2024‐A‐3267‐Diabetes) at the American Diabetes Association's 84th Scientific Sessions, 21–24 June 2024 in Orlando, Florida.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1462-8902
1463-1326
1463-1326
DOI:10.1111/dom.16121